Repositorio
Institucional

Kalergis, Alexis M.

Reyes, Humberto

Diethelm-Varela, Benjamin

Mendez, Constanza

Rebolledo-Zelada, Diego

Lillo-Dapremont, Bastian

Munoz, Sergio R.

Bueno, Susan M.

Gonzalez, Pablo A.

Contribution of Two-Dose Vaccination Toward the Reduction of COVID-19 Cases, ICU Hospitalizations and Deaths in Chile Assessed Through Explanatory Generalized Additive Models for Location, Scale, and Shape

FRONTIERS MEDIA SA

FRONTIERS IN PUBLIC HEALTH

en

ObjectivesTo assess the impact of the initial two-dose-schedule mass vaccination campaign in Chile toward reducing adverse epidemiological outcomes due to SARS-CoV-2 infection. MethodsPublicly available epidemiological data ranging from 3 February 2021 to 30 September 2021 were used to construct GAMLSS models that explain the beneficial effect of up to two doses of vaccination on the following COVID-19-related outcomes: new cases per day, daily active cases, daily occupied ICU beds and daily deaths. ResultsAdministered first and second vaccine doses, and the statistical interaction between the two, are strong, statistically significant predictors for COVID-19-related new cases per day (R-2 = 0.847), daily active cases (R-2 = 0.903), ICU hospitalizations (R-2 = 0.767), and deaths (R-2 = 0.827). ConclusionOur models stress the importance of completing vaccination schedules to reduce the adverse outcomes during the pandemic. Future work will continue to assess the influence of vaccines, including booster doses, as the pandemic progresses, and new variants emerge. Policy ImplicationsThis work highlights the importance of attaining full (two-dose) vaccination status and reinforces the notion that a second dose provides increased non-additive protection. The trends we observed may also support the inclusion of booster doses in vaccination plans. These insights could contribute to guiding other countries in their vaccination campaigns.

artículo original

This work was supported by the following funding agencies: ANID-Subdireccion de Capital Humano/Doctorado Nacional, Agencia Nacional de Investigacion y Desarrollo (ANID), Millennium Institute on Immunology and Immunotherapy (ICN09_016/ ICN 2021_045, former P09/016-F) and FONDECYT grant 1190830, 1190864, 1170964 from the Agencia Nacional de Investigacion y Desarrollo (ANID), Regional Government of Antofagasta through the Innovation Fund for Competitiveness FIC-R 2017 (BIP Code: 30488811-0), COPEC-UC 2020.R.001, and Globalgiving-3M. AK is a Helen C. Levitt Visiting Professor at the Department of Microbiology and Immunology of the University of Iowa.

Este trabajo fue apoyado por las siguientes agencias financiadoras: ANID-Subdireccion de Capital Humano/Doctorado Nacional, Agencia Nacional de Investigación y Desarrollo (ANID), Instituto Milenio de Inmunología e Inmunoterapia (ICN09_016/ICN 2021_045, ex P09/016-F) y Subsidio FONDECYT 1190830, 1190864, ​​1170964 de la Agencia Nacional de Investigación y Desarrollo (ANID), Gobierno Regional de Antofagasta a través del Fondo de Innovación para la Competitividad FIC-R 2017 (Código BIP: 30488811-0), COPEC-UC 2020. R.001 y Globalgiving-3M. AK es profesora invitada Helen C. Levitt en el Departamento de Microbiología e Inmunología de la Universidad de Iowa.

This work was supported by the following funding agencies: ANID-Subdireccion de Capital Humano/Doctorado Nacional, Agencia Nacional de Investigacion y Desarrollo (ANID), Millennium Institute on Immunology and Immunotherapy (ICN09_016/ ICN 2021_045; former P09/016-F) and FONDECYT grant 1190830, 1190864, 1170964 from the Agencia Nacional de Investigacion y Desarrollo (ANID), Regional Government of Antofagasta through the Innovation Fund for Competitiveness FIC-R 2017 (BIP Code: 30488811-0), COPEC-UC 2020.R.001, and Globalgiving-3M. AK is a Helen C. Levitt Visiting Professor at the Department of Microbiology and Immunology of the University of Iowa.

Este trabajo fue apoyado por las siguientes agencias financiadoras: ANID-Subdireccion de Capital Humano/Doctorado Nacional, Agencia Nacional de Investigación y Desarrollo (ANID), Instituto Milenio de Inmunología e Inmunoterapia (ICN09_016/ICN 2021_045; ex P09/016-F) y Subsidio FONDECYT 1190830, 1190864, ​​ 1170964 de la Agencia Nacional de Investigación y Desarrollo (ANID), Gobierno Regional de Antofagasta a través del Fondo de Innovación para la Competitividad FIC-R 2017 (Código BIP: 30488811-0), COPEC-UC 2020. R.001 y Globalgiving-3M. AK es profesora invitada Helen C. Levitt en el Departamento de Microbiología e Inmunología de la Universidad de Iowa.

10.3389/fpubh.2022.815036

PDF

GAMLSS models

COVID-19

vaccination

ICU hospitalizations

explanatory models

Salud pública

ambiental y ocupacional

Modelos GAMLSS

COVID-19

vacunación

hospitalizaciones en UCI

modelos explicativos

Epidemiología

Salud Pública y Ambiental

Medicina General e Interna

Contribution of Two-Dose Vaccination Toward the Reduction of COVID-19 Cases, ICU Hospitalizations and Deaths in Chile Assessed Through Explanatory Generalized Additive Models for Location, Scale, and Shape

artículo original

version publicada

CC BY 4.0

CC BY 4.0

acceso abierto

acceso abierto

ANID-FONDECYT 1190830

ANID-FONDECYT 1190864

ANID-FONDECYT 1170964

COPEC-UC 2020.R.001

IMII ICN09_016

IMII ICN 2021_045

FIC-R 30488811-0

ANID FONDECYT 1190830

ANID FONDECYT 1190864

ANID FONDECYT 1170964

WOS:000838929900001